Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

SangStat SangCya

Executive Summary

Rite Aid is instructing its pharmacies to begin replacing Novartis' cyclosporine Neoral oral solution with SangStat's less expensive product for the prevention of graft rejection following organ transplant, SangStat CEO Jean-Jacques Bienaime announced Jan. 11. The Rite Aid memo also directs pharmacists to purchase the SangStat product from McKesson. The company is expecting European approval of the cyclosporine in the first quarter of 1999, Bienaime said. Marketing approval will be sought in first half of 1999 in the U.S. and EU for cyclosporine capsules following positive results from a bioequivalence trial vs. Neoral. The single-dose, randomized, cross-over trial involved 27 healthy volunteers
Advertisement
Advertisement
UsernamePublicRestriction

Register

PS033495

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel